Physician profile
Richard Mohammed
NPI 1295350486
$4,733.95
in general payments reported to CMS, 2019-2025
33 companies · $17.03 in 2025
The $17.03 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,361 · 2022: $2,543 · 2023: $754 · 2024: $58.43 · 2025: $17.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,199.30 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $544.65 | 2021-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $393.41 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $315.05 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Teva Pharmaceuticals USA, INC. | $221.97 | 2021-2023 | Ajovy |
| Scilex Pharmaceuticals INC. | $199.19 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.23 | 2021-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.79 | 2021-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $159.25 | 2021-2022 | |
| Amgen INC. | $158.87 | 2021-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $155.22 | 2021-2022 | |
| Pfizer INC. | $123.82 | 2021-2023 | |
| Glaxosmithkline, LLC. | $122.47 | 2021-2023 | Trelegy Ellipta, Boostrix, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $101.54 | 2022 | |
| Lilly USA, LLC | $92.80 | 2022-2023 | Jardiance, Emgality |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.65 | 2022-2023 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.79 | 2022-2023 | |
| Ibsa Pharma INC. | $71.66 | 2021-2022 | |
| Lundbeck LLC | $45.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.11 | 2022-2023 | |
| Seqirus USA INC | $36.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.20 | 2023 | |
| Althera Pharmaceuticals LLC | $29.55 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $25.21 | 2022 | |
| Inspire Medical Systems, INC. | $24.18 | 2024 | Inspire |
| Abbott Laboratories | $23.20 | 2022 | |
| Eisai INC. | $19.07 | 2021 | |
| Corium, LLC | $18.19 | 2023 | Adlarity |
| Axsome Therapeutics, INC. | $17.86 | 2023 | Auvelity |
| Optinose US, INC. | $17.03 | 2025 | |
| Xeris Pharmaceuticals, INC. | $14.59 | 2022 | |
| Horizon Therapeutics Plc | $13.06 | 2022 | |
| Vistapharm, INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.